Abstract
The 2020 ESC Digital Experience congress gathered 125 thousand participants from 211 countries. Four new guidelines were released including diagnosis and management of atrial fibrillation, management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, sports cardiology and exercise in patients with cardiovascular disease, and management of adult congenital heart disease. Several landmark clinical trials were presented including studies assessing: the effects of SGLT2 inhibitors (DAPA-CKD and EMPEROR-Reduced trials), potential benefits of colchicine (LoDoCo2 trial) and safety of drugs blocking renin–angiotensin in COVID-19 patients (BRACE CORONA trial). New meta-analyses confirmed benefits of antihypertensive treatment and cancer-related safety of cardiovascular drugs. This short review summarizes the most important results presented during the congress and discusses their clinical implications.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
